

NSW Cancer Research Education

Statewide Seminar Series 2024

Tuesday 21 May 12.30 - 1.30 pm

Molecular Tumour Board: The potential role of precision medicine in altering the poor outcomes in pancreas cancer



Dr Frank Lin

Medical oncologist and clinical informatician, The Garvan Institute of Medical Research



Dr Milita Zaheed

Medical Oncologist, Prince of Wales Hospital



Dr John Grady

Senior Bioinformatics Software Engineer, The Garvan Institute of Medical Research



Professor David Goldstein

Conjoint Clinical Professor, UNSW, Sydney

Chair: Clinical Professor Rosemary Balleine. Clinical & Strategic Partnerships Lead, Sydney Cancer Partners, The University of Sydney

21
2024 MAY



12:30 - 1:30
PM PM



Online
Webinar

[REGISTER NOW](#)

Supported by the Cancer Institute NSW Translation Cancer Research Capacity Building Grants



Session Information

Pancreatic cancer has a poor prognosis and an urgent need for new effective treatments. In this educational Molecular Tumour Board session, we will hear an update on the molecular features of pancreatic cancer and their relevance to clinical management. This will be followed by a series of informative case presentations with discussion from an expert multi-disciplinary team. The session will give insight to the clinical interpretation of molecular data, its relevance in current practice and the opportunities it presents for improving pancreatic cancer outcomes.

Speakers



Dr Frank Lin is a medical oncologist and clinical informatician based in Sydney. He currently holds conjoint research appointments at the Garvan Institute of Medical Research, NHMRC Clinical Trials Centre (University of Sydney), and the Maridulu Budyari Gumal (SPHERE) Cancer Clinical Academic Group (UNSW, Sydney). Frank's research work focuses on empowering genomic decision-making, precision diagnostics, and multidisciplinary cancer care through artificial intelligence and machine learning. He is co-investigator of several clinical trials in early phase drug development, responsible for developing biomarker-driven basket trials of targeted and immunotherapy across cancer types. He established and maintains the TOPOGRAPH precision oncology knowledgebase, as well as several open-source resources for genomic decision-support, electronic medical record analytics, and natural language processing. He is a key member of the molecular tumour board with the MoST program. He is chief and co-investigator on several grants.



Dr Milita Zaheed is a Medical Oncologist and works as a staff specialist in Cancer Genetics at The Prince of Wales Hospital. She is the medical lead for ACT Cancer Genetics service. She is undertaking a PhD in cancer genetics through The Garvan Institute investigating opportunities to improve identification of cancer predisposition syndromes. She is an active member of the Molecular Screening and Therapeutics (MoST) study. Her interests are in education and equity of care of underserved populations. Milita is the current chair of NSW/ACT Familial Cancer Clinics community of practice, a committee member of Young Oncologists Group of Australia and Global Oncology Special Interest Group of Clinical Oncology Society of Australia.



Dr John Grady is a Senior Bioinformatics Software Engineer at the Garvan Institute and is responsible for the bioinformatics of the MoST (Molecular Screening and Therapeutics) Program at the Garvan Institute. John completed his PhD in mitochondrial genetics at Newcastle University in the UK in 2014 and moved to Australia in 2016 to take up a role at the University of Queensland in cancer genomics. He moved to the Garvan in April 2017 to take up his role with the MoST program. Prior to completing his PhD John worked mainly as a software engineer in a variety of roles over the years, including several years working on the Swiss and German stock markets and four years as a statistician and IT consultant for the Ethiopian Ministry of Education in Addis Ababa, before moving into scientific research.



Professor David Goldstein is a senior medical oncologist oncology, with multifaceted clinical interests, centring on the treatment of gastrointestinal malignancies including pancreas cancer, colorectal cancers, anal carcinoma, hepatobiliary, upper gastrointestinal malignancy. He has been involved in a variety of clinical research projects ranging from laboratory basic science to novel therapeutics trials to psychosocial aspects of Cancer care. As the Principal Investigator for numerous NHMRC and Cancer Australia funded trials, including multinational studies, he has demonstrated leadership in advancing cancer treatment. He is the co-ordinating investigator for the MoST-P project a part of the broader MoST precision medicine program.